SEC Filing Summary: Owens & Minor, Inc. (8-K)
Business Context and Reporting Period
Company: Owens & Minor, Inc. (Note: Metadata referenced Accendra Health Inc., but the filing text identifies Owens & Minor, Inc.)
Date: April 4, 2025
Event: Entry into a Material Definitive Agreement (Item 1.01) and Creation of a Direct Financial Obligation (Item 2.03).
Context: The Company completed a private offering of $1.0 billion in senior secured notes to finance the proposed acquisition of Rotech Healthcare Holdings Inc. ("Rotech").
Key Financial Metrics and Debt Structure
- Debt Issuance: $1,000,000,000 aggregate principal amount of 10.000% Senior Secured Notes due 2030 ("New Notes").
- Interest Rate: 10.000% per annum, payable semi-annually in arrears (first payment October 15, 2025).
- Security Status:
- Pre-Acquisition: Secured by a first-priority lien on the Escrow Account holding gross proceeds.
- Post-Acquisition: Secured by a first-priority lien on substantially all existing and future assets of the Company and guarantors (subject to permitted liens).
- Guarantees: Guaranteed by existing and future wholly-owned domestic restricted subsidiaries. Post-acquisition, Rotech and its subsidiaries will also guarantee the notes.
- Liquidity: Gross proceeds are held in a segregated escrow account pending the consummation of the Rotech acquisition.
Material Changes and Transaction Terms
The filing details the terms of the New Notes, which differ from standard unsecured debt due to the specific escrow arrangement and acquisition contingency.
- Special Mandatory Redemption: If the Rotech acquisition is not consummated by October 6, 2025, or upon certain other events, the escrow funds will be used to redeem the New Notes at 100% of the initial issue price plus accrued interest.
- Optional Redemption:
- Pre-April 15, 2027: Redeemable at 100% principal plus accrued interest and a "make-whole" premium.
- Equity Proceeds: Up to 40% of principal redeemable at 110% using net cash proceeds from equity offerings.
- Annual Redemption: Up to 10% of principal redeemable at 103% during each 12-month period post-escrow release.
- PHS Disposition: Redeemable at 103% using proceeds from the sale of the Products & Healthcare Services segment.
- Change of Control: Triggers a mandatory offer to repurchase notes at 101% of principal (or 105% in case of a Non-Qualifying PHS Disposition) plus accrued interest.
Covenants, Risks, and Contingencies
- Covenants: The Indenture restricts additional indebtedness, dividends, stock repurchases, investments, liens, asset sales, and affiliate transactions. Most covenants are waived if the New Notes are rated investment grade by two major rating agencies.
- PHS Disposition Paydown: If the Company sells its Products & Healthcare Services segment, at least 50% of the net available cash must be used to prepay first lien obligations outstanding prior to the New Notes.
- Events of Default: Include failure to pay principal/interest, covenant breaches, invalidity of liens, and bankruptcy/insolvency. Default allows for acceleration of the principal and accrued interest.
- Contingency: The release of funds to the Company is contingent on the successful closing of the Rotech acquisition. Failure to close by the specified date triggers mandatory redemption.
Investor Verification Checklist
- Verify the status of the Rotech Healthcare Holdings Inc. acquisition and the likelihood of closing before October 6, 2025.
- Confirm the current credit rating of the New Notes to determine if restrictive covenants are active or waived.
- Review the "New Indenture" (Exhibit 4.1) for specific definitions of "permitted liens" and "excluded property" affecting the security package.
- Assess the Company's ability to service the 10% interest rate on $1 billion of new debt alongside existing obligations.
- Monitor any potential "PHS Disposition" (sale of Products & Healthcare Services segment) which would trigger mandatory debt paydowns.